CA2963973C - Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors - Google Patents
Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors Download PDFInfo
- Publication number
- CA2963973C CA2963973C CA2963973A CA2963973A CA2963973C CA 2963973 C CA2963973 C CA 2963973C CA 2963973 A CA2963973 A CA 2963973A CA 2963973 A CA2963973 A CA 2963973A CA 2963973 C CA2963973 C CA 2963973C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- aryl
- group
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D515/18—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Biomedical Technology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462063176P | 2014-10-13 | 2014-10-13 | |
| US62/063,176 | 2014-10-13 | ||
| US201562104274P | 2015-01-16 | 2015-01-16 | |
| US62/104,274 | 2015-01-16 | ||
| PCT/US2015/055317 WO2016061097A1 (en) | 2014-10-13 | 2015-10-13 | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2963973A1 CA2963973A1 (en) | 2016-04-21 |
| CA2963973C true CA2963973C (en) | 2023-01-10 |
Family
ID=55654998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2963973A Active CA2963973C (en) | 2014-10-13 | 2015-10-13 | Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US9663535B2 (2) |
| EP (1) | EP3207031B1 (2) |
| JP (1) | JP6678679B2 (2) |
| KR (1) | KR102569226B1 (2) |
| CN (1) | CN107108527B (2) |
| AU (1) | AU2015333738B2 (2) |
| BR (1) | BR112017007708B8 (2) |
| CA (1) | CA2963973C (2) |
| ES (1) | ES2879441T3 (2) |
| IL (1) | IL251595B (2) |
| MX (1) | MX389198B (2) |
| WO (1) | WO2016061097A1 (2) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102569226B1 (ko) | 2014-10-13 | 2023-08-22 | 아트린 파마슈티컬스 엘엘씨 | 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 |
| WO2017180723A1 (en) * | 2016-04-12 | 2017-10-19 | Atrin Pharmaceuticals LLC | Ataxia telengiectasia and rad3-related (atr) inhibitors and methods of their use |
| WO2018218197A2 (en) | 2017-05-26 | 2018-11-29 | Board Of Regents, The University Of Texas System | Tetrahydropyrido[4,3-d]pyrimidine inhibitors of atr kinase |
| HUE066043T2 (hu) | 2017-07-13 | 2024-07-28 | Univ Texas | A TR kináz beterociklusos inhibitorai |
| JP7290627B2 (ja) | 2017-08-17 | 2023-06-13 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| WO2019055657A1 (en) * | 2017-09-14 | 2019-03-21 | The Board Of Trustees Of The Leland Stanford Junior University | BAF COMPLEX MODULATION COMPOUNDS AND METHODS OF USE |
| JP7341156B2 (ja) | 2018-03-16 | 2023-09-08 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | Ａｔｒキナーゼの複素環式阻害剤 |
| CN110357905B (zh) * | 2018-03-26 | 2021-10-01 | 武汉誉祥医药科技有限公司 | 作为蛋白激酶抑制剂的大环类衍生物及其制备方法和用途 |
| US11980613B2 (en) | 2018-07-12 | 2024-05-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for reversing HIV latency using BAF complex modulating compounds |
| CN110950890B (zh) * | 2018-09-27 | 2022-07-01 | 北京赛林泰医药技术有限公司 | 取代的咪唑并[4,5-c]喹啉大环化合物作为多靶点激酶抑制剂 |
| CR20210281A (es) | 2018-10-30 | 2021-10-25 | Repare Therapeutics Inc | Compuestos, composiciones farmacéuticas y métodos de preparación de compuestos y de uso como inhibidores de la cinasa atr |
| EP4230628B1 (en) | 2020-10-16 | 2025-10-15 | Shanghai de Novo Pharmatech Co., Ltd. | Triheterocyclic derivative, and pharmaceutical composition and application thereof |
| KR20250006892A (ko) | 2022-04-14 | 2025-01-13 | 아프레아 테라퓨틱스, 인크. | Atr 저해제 |
| IL317573A (en) | 2022-06-15 | 2025-02-01 | Astrazeneca Ab | Combination therapy for cancer treatment |
| WO2025181153A1 (en) | 2024-03-01 | 2025-09-04 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with pi3k alpha inhibitors |
| WO2025229051A1 (en) | 2024-05-03 | 2025-11-06 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with antiandrogen agent |
| WO2025233224A1 (en) | 2024-05-09 | 2025-11-13 | F. Hoffmann-La Roche Ag | Use of atr inhibitors in combination with anti-pd(l)1 therapy |
| WO2026064575A1 (en) | 2024-09-19 | 2026-03-26 | Aprea Therapeutics, Inc. | Methods for treating cancer |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2517256C (en) * | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
| US7163939B2 (en) * | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| ES2663222T3 (es) * | 2008-12-19 | 2018-04-11 | Vertex Pharmaceuticals Incorporated | Derivados de pirazina útiles como inhibidores de la quinasa ATR |
| JP2013526540A (ja) | 2010-05-12 | 2013-06-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ａｔｒキナーゼ阻害剤として有用な化合物 |
| WO2012125603A1 (en) | 2011-03-16 | 2012-09-20 | Cephalon, Inc. | Macrocyclic compounds as alk, fak and jak2 inhibitors |
| HUE034118T2 (en) * | 2012-03-06 | 2018-01-29 | Pfizer | Macrocyclic derivatives for the treatment of proliferative diseases |
| EP2836485B1 (en) * | 2012-03-17 | 2018-01-10 | Polyphor Ag | Conformationally constrained, fully synthetic macrocyclic compounds |
| CN104513253A (zh) * | 2013-10-01 | 2015-04-15 | 南京波尔泰药业科技有限公司 | 用于治疗增殖性疾病的大环化合物 |
| KR102569226B1 (ko) | 2014-10-13 | 2023-08-22 | 아트린 파마슈티컬스 엘엘씨 | 운동실조 모세혈관확장증 및 Rad3-관련 (ATR) 단백질 키나제 억제제 |
-
2015
- 2015-10-13 KR KR1020177012838A patent/KR102569226B1/ko active Active
- 2015-10-13 AU AU2015333738A patent/AU2015333738B2/en active Active
- 2015-10-13 BR BR112017007708A patent/BR112017007708B8/pt active Search and Examination
- 2015-10-13 EP EP15850553.7A patent/EP3207031B1/en active Active
- 2015-10-13 US US14/881,680 patent/US9663535B2/en active Active
- 2015-10-13 MX MX2017004515A patent/MX389198B/es unknown
- 2015-10-13 JP JP2017538930A patent/JP6678679B2/ja active Active
- 2015-10-13 WO PCT/US2015/055317 patent/WO2016061097A1/en not_active Ceased
- 2015-10-13 ES ES15850553T patent/ES2879441T3/es active Active
- 2015-10-13 CA CA2963973A patent/CA2963973C/en active Active
- 2015-10-13 CN CN201580067182.7A patent/CN107108527B/zh active Active
-
2017
- 2017-04-05 IL IL251595A patent/IL251595B/en unknown
- 2017-04-27 US US15/498,631 patent/US9981989B2/en active Active
-
2018
- 2018-04-12 US US15/951,302 patent/US10196405B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112017007708A2 (pt) | 2017-12-19 |
| US20160102104A1 (en) | 2016-04-14 |
| US9663535B2 (en) | 2017-05-30 |
| US20170226130A1 (en) | 2017-08-10 |
| AU2015333738A1 (en) | 2017-05-04 |
| CA2963973A1 (en) | 2016-04-21 |
| BR112017007708B8 (pt) | 2023-10-24 |
| US9981989B2 (en) | 2018-05-29 |
| WO2016061097A1 (en) | 2016-04-21 |
| BR112017007708A8 (2) | 2017-12-19 |
| MX2017004515A (es) | 2017-10-31 |
| EP3207031A1 (en) | 2017-08-23 |
| AU2015333738B2 (en) | 2020-03-26 |
| JP2017531041A (ja) | 2017-10-19 |
| IL251595B (en) | 2022-04-01 |
| MX389198B (es) | 2025-03-20 |
| KR20170082532A (ko) | 2017-07-14 |
| CN107108527A (zh) | 2017-08-29 |
| BR112017007708B1 (pt) | 2023-07-25 |
| US20180230168A1 (en) | 2018-08-16 |
| KR102569226B1 (ko) | 2023-08-22 |
| EP3207031B1 (en) | 2021-04-14 |
| US10196405B2 (en) | 2019-02-05 |
| IL251595A0 (en) | 2017-06-29 |
| JP6678679B2 (ja) | 2020-04-08 |
| CN107108527B (zh) | 2022-08-02 |
| EP3207031A4 (en) | 2018-02-14 |
| ES2879441T3 (es) | 2021-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2963973C (en) | Macrocylic compounds as ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors | |
| CA2969090C (en) | Triazolopyrimidine compounds and uses thereof | |
| CA2892608C (en) | Compounds useful as inhibitors of atr kinase | |
| CN116554151A (zh) | 驱动蛋白kif18a抑制剂及其应用 | |
| BR112021002327A2 (pt) | derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4,5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos relacionados como inibidores de ptpn11(shp2) para o tratamento do câncer | |
| BR112016012734B1 (pt) | Composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto | |
| AU2017258781B2 (en) | Di-substituted pyrazole compounds for the treatment of diseases | |
| US12234218B2 (en) | Heterocyclic compounds as modulators of mGluR7 | |
| JP2021535909A (ja) | 高活性ｓｔｉｎｇタンパク質アゴニスト化合物 | |
| EA034235B1 (ru) | Новые композиции, их использование и способы получения | |
| TW200936140A (en) | Substituted arylamide oxazepinopyrimidone derivatives | |
| CA3023032A1 (en) | Substituted 2,4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| WO2017083756A1 (en) | Heterocyclic compounds for the treatment of disease | |
| WO2023109751A1 (zh) | 嘧啶或吡啶类衍生物及其医药用途 | |
| CN118434743A (zh) | 三环杂环类 | |
| CN106065018A (zh) | 取代的吲哚化合物及其使用方法和用途 | |
| HK1235837B (en) | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors | |
| HK1235837A1 (en) | Ataxia telengiectasia and rad3-related (atr) protein kinase inhibitors | |
| HK40001081A (en) | Substituted 2, 4-diamino-quinoline derivatives for use in the treatment of proliferative diseases | |
| BR112018072169B1 (pt) | Compostos isoquinolin-3-il carboxamidas, composição farmacêutica compreendendo os ditos compostos e uso terapêutico dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20201006 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241018 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241018 |